BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT

This study is testing whether a CAR-T cell therapy — a treatment where your own immune cells are reprogrammed to attack cancer — can help high-risk multiple myeloma (a blood cancer) patients who still have detectable cancer after their initial treatment and stem cell transplant. **You may be eligible if...** - You are 18 or older - You have been newly diagnosed with high-risk multiple myeloma - You have completed initial treatment (induction therapy) and a stem cell transplant - Tests show that cancer cells are still detectable in your bone marrow after transplant (called MRD positive) **You may NOT be eligible if...** - You have already been treated for multiple myeloma with a prior BCMA-targeted therapy - You have active infections, significant organ damage, or other serious health conditions - You have another active cancer - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.